Literature DB >> 17889625

Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages.

Charlotte Andersson1, Munir M Zaman, Amanda B Jones, Steven D Freedman.   

Abstract

BACKGROUND: Cystic fibrosis (CF) is characterized by an excessive inflammatory response in epithelial cells and macrophages. In CF mice, lung inflammation can be abrogated by oral treatment with docosahexaenoic acid (DHA). Since PPARs and LXRs are important regulators of inflammation and fatty acid metabolism in macrophages, we hypothesized that these pathways are dysregulated in CF macrophages and are corrected with DHA treatment.
METHODS: Peritoneal macrophages were obtained from wild type and cftr(-/-) mice. LPS induced cytokine secretion and NFkappaB activity were analyzed with and without oral DHA treatment. The expression and activity of PPARalpha,gamma, delta and LXRalpha were analyzed by RT-PCR and EMSA.
RESULTS: LPS induced TNFalpha and IL-6 secretion and NFkappaB p65 activity were increased in CF macrophages. This was associated with low basal PPARgamma expression and attenuated LPS induced induction of PPARdelta, LXRalpha and ABCA1. DHA pretreatment in vivo decreased TNFalpha secretion and p65 activity, and increased PPARalpha and gamma expression and function. The effects of DHA could be reproduced by PPAR agonists and blocked by a PPARalpha antagonist.
CONCLUSION: Impaired regulation of nuclear receptors may contribute to the abnormal LPS induced signaling in CF macrophages and is reversed by DHA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17889625     DOI: 10.1016/j.jcf.2007.05.004

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  19 in total

1.  Role of PPARα in the attenuation of bile acid-induced apoptosis by omega-3 long-chain polyunsaturated fatty acids in cultured hepatocytes.

Authors:  Emma M Tillman; Peihong Guan; Timothy J Howze; Richard A Helms; Dennis D Black
Journal:  Pediatr Res       Date:  2016-01-12       Impact factor: 3.756

2.  Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs.

Authors:  Nicholas W Keiser; Susan E Birket; Idil A Evans; Scott R Tyler; Adrianne K Crooke; Xingshen Sun; Weihong Zhou; Joseph R Nellis; Elizabeth K Stroebele; Kengyeh K Chu; Guillermo J Tearney; Mark J Stevens; J Kirk Harris; Steven M Rowe; John F Engelhardt
Journal:  Am J Respir Cell Mol Biol       Date:  2015-06       Impact factor: 6.914

3.  Mesenchymal Stem Cell Soluble Mediators and Cystic Fibrosis.

Authors:  Morgan T Sutton; David Fletcher; Nicole Episalla; Lauren Auster; Sukhmani Kaur; Mary Chandler Gwin; Michael Folz; Dante Velasquez; Varun Roy; Rolf van Heeckeren; Donald P Lennon; Arnold I Caplan; Tracey L Bonfield
Journal:  J Stem Cell Res Ther       Date:  2017-09-22

4.  Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis.

Authors:  Emanuela M Bruscia; Ping-Xia Zhang; Ayano Satoh; Christina Caputo; Ruslan Medzhitov; Ambika Shenoy; Marie E Egan; Diane S Krause
Journal:  J Immunol       Date:  2011-05-18       Impact factor: 5.422

5.  Reduced caveolin-1 promotes hyperinflammation due to abnormal heme oxygenase-1 localization in lipopolysaccharide-challenged macrophages with dysfunctional cystic fibrosis transmembrane conductance regulator.

Authors:  Ping-Xia Zhang; Thomas S Murray; Valeria R Villella; Eleonora Ferrari; Speranza Esposito; Anthony D'Souza; Valeria Raia; Luigi Maiuri; Diane S Krause; Marie E Egan; Emanuela M Bruscia
Journal:  J Immunol       Date:  2013-04-19       Impact factor: 5.422

6.  Reduction in dietary omega-6 polyunsaturated fatty acids: eicosapentaenoic acid plus docosahexaenoic acid ratio minimizes atherosclerotic lesion formation and inflammatory response in the LDL receptor null mouse.

Authors:  Shu Wang; Dayong Wu; Nirupa R Matthan; Stefania Lamon-Fava; Jaime L Lecker; Alice H Lichtenstein
Journal:  Atherosclerosis       Date:  2008-09-02       Impact factor: 5.162

Review 7.  Anti-inflammatory therapies for cystic fibrosis-related lung disease.

Authors:  David P Nichols; Michael W Konstan; James F Chmiel
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

Review 8.  Cystic Fibrosis Lung Immunity: The Role of the Macrophage.

Authors:  Emanuela M Bruscia; Tracey L Bonfield
Journal:  J Innate Immun       Date:  2016-06-24       Impact factor: 7.349

9.  Potential of anti-inflammatory treatment for cystic fibrosis lung disease.

Authors:  Jennifer L Taylor-Cousar; Kelsey A Von Kessel; Robert Young; David P Nichols
Journal:  J Inflamm Res       Date:  2010-08-10

10.  Expression of PPARγ and paraoxonase 2 correlated with Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  Phoebe E Griffin; Louise F Roddam; Yvonne C Belessis; Roxanne Strachan; Sean Beggs; Adam Jaffe; Margaret A Cooley
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.